We will soon begin repaving the main driveway outside the Yawkey, Menino, and Moakley buildings. Weather permitting, driveway closures are scheduled for the following weekends, from Friday at 8 p.m. through Sunday at 8 p.m., on the following dates: Sept. 19-21, Sept. 26-28, Oct. 17-19, and Oct. 24-26. 

Access Changes During Construction:

Pedestrian Access: Patients and visitors will be able to enter Moakley through the entrance on East Concord Street.    

Vehicle Access: Vehicular traffic should use the designated drop-off and pick-up area on East Concord Street or the 710 Albany Street Garage. Signage will indicate where metered parking has been blocked off to create a drop-off/pick-up zone (on E. Concord between Harrison and the Moakley side entrance). 

Learn more about our campus redesign. 

Below is a list of available discarded clinical and prospective cohort samples. Our samples are coded with a unique ID at time of release to the investigator. Samples are paired with a minimal amount of clinical data, further described here.

Discarded Clinical Samples

  • Transport media from nasopharyngeal swabs (COVID+ and COVID- patients)
  • Transport media from oropharyngeal swabs (COVID+ and COVID- patients)
  • Serum (COVID+ and COVID- patients)
  • Plasma (COVID+ and COVID- patients)

Prospective Cohort Samples

Inpatients 

Patients admitted to BMC with COVID-19 disease. Samples are collected weekly from time of admission up until discharge

  • Transport media from nasopharyngeal swabs 
  • Transport media from oropharyngeal swabs
  • Saliva
  • Peripheral blood mononuclear cell (PBMCs)
  • Serum 
  • Plasma
  • RNA stabilization tubes (i.e., BD PAXgene® tubes)
  • Urine
  • Stool

Ambulatory patients

Patients diagnosed with COVID-19 in the ambulatory clinic setting at BMC. Samples are collected within the first week after diagnosis, one month after diagnosis, and two months after diagnosis.

  • Transport media from nasopharyngeal swabs
  • Transport media from oropharyngeal swabs
  • Saliva
  • PBMCs
  • Serum
  • Plasma
  • RNA stabilization tubes (i.e., BD PAXgene® tubes)

COVID-19 survivors

Individuals diagnosed with COVID-19 who are >= 2 weeks out from resolution of acute symptoms. Samples are collected 1, 2, 3, and 6, 12, 18 and 24 months after diagnosis.

  • Transport media from nasopharyngeal swabs
  • Transport media from oropharyngeal swabs
  • Saliva
  • PBMCs
  • Serum
  • Plasma
  • RNA stabilization tubes (i.e., BD PAXgene® tubes)